Treatment of gastrointestinal problems in cystic fibrosis
- 175 Downloads
The gastrointestinal (GI) manifestations of cystic fibrosis (CF) are varied and include pancreatic insufficiency, meconium ileus, distal intestinal obstruction syndrome (DIOS), liver disease, and other less common manifestations. Treatment of pancreatic insufficiency consists of providing appropriate pancreatic enzyme replacement therapy and may include raising duodenal pH to allow for optimal action of these enzymes. Despite a number of pancreatic enzyme replacement products, malabsorption cannot be normalized. Management of DIOS depends on the severity of the symptoms; adequate hydration is very important. Polyethylene glycol solutions are being increasingly used. The precipitating cause of the episode of DIOS should be looked for so future episodes can be prevented. Liver disease is relatively silent and annual monitoring of liver function and status is recommended. Treatment is mainly supportive and the role of ursodeoxycholic acid in the prevention of cirrhosis needs to be better defined. Nutritional status is an important part of management of all GI and liver manifestations of CF. A team approach and the assistance of a registered dietitian are extremely valuable in managing the GI and liver manifestations of CF.
KeywordsCystic Fibrosis Transjugular Intrahepatic Portosystemic Shunt Rectal Prolapse Pancreatic Enzyme Main Drug Interaction
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Zielenski J, Corey M, Rozmahel R, et al.: Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet 1999, 2:128–129.Google Scholar
- 10.Siafakas C, Vottler TP, Andersen JM: Rectal prolapse in pediatrics. Clin Pediatr 1999, 38:63–72.Google Scholar
- 12.Hassall E, Israel DM, Davidson AG, et al.: Barrett’s esophagus in children with cystic fibrosis: not a coincidental association. Am J Gastroenterol 1993, 8:1934–1938.Google Scholar
- 16.Borowitz DS, Grand RJ, Durie PR, et al.: Use of pancreatic enzyme supplements with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr 2001, 127:681–684. This is the first and most comprehensive report from the CF Foundation with guidelines for pancreatic enzyme-replacement therapy and management.Google Scholar
- 21.Baker RD, Borowitz D, Stallings VA: Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002, 35:246–259. This is a comprehensive summary of the nutritional aspects of the management in CF and provides the reader with some excellent information.PubMedCrossRefGoogle Scholar
- 37.Cheng K, Ashby D, Smythe R: Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database of Systematic Reviews 2000, 2:CD000222.Google Scholar
- 38.Colombo C, Bertolini E, Assaisso ML, et al.: Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paeditr 1993, 82:562–565.Google Scholar
- 39.Strandvick B, Hultcrantz R: Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. Liver 1994, 14:32–36.Google Scholar